Bristol Myers Squibb BMY
NYSE BMY
$63.88 +1.02 (+1.62%)
As of: Sep 28, 2026 · 3:59 PM EDT

Bristol Myers Squibb (BMY) Gains from Sales and Divestitures (2009)

Updated

Bristol Myers Squibb's Gains from Sales and Divestitures came in at $292 million for Q4 2009.

Analysis

Bristol Myers Squibb (BMY) Gains from Sales and Divestitures (2009) Analysis & Trends

For FY2009, Bristol Myers Squibb's Gains from Sales and Divestitures was $367 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 653.54 Bn 572.07 Bn 17.26 Bn
2 AbbVie 467.01 Bn 440.17 Bn 12.70 Bn
3 Merck 367.16 Bn 321.59 Bn 12.21 Bn
4 Novartis Ag 277.56 Bn 233.43 Bn 11.24 Bn
5 Astrazeneca 258.23 Bn 231.79 Bn 12.86 Bn
6 Amgen 224.14 Bn 179.54 Bn 7.24 Bn
7 Gilead Sciences 187.30 Bn 161.42 Bn 6.22 Bn
8 Pfizer 163.47 Bn 110.41 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.31 Bn 105.31 Bn 2.84 Bn
10 Bristol Myers Squibb 128.45 Bn 79.72 Bn 9.25 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2009 292.00 Mn
Sep 30, 2009 16.00 Mn
API Access

Bristol Myers Squibb Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=BMY&period=max&api_key=YOUR_API_KEY